Stocktoria
GYRE THERAPEUTICS, INC. GYRE
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2006-04-12
GYRE THERAPEUTICS, INC. financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $116.6M | $105.8M | $113.5M | $102.3M | $7.3M | $20.9M | — | $6,000 | $1.0M | — |
| Gross profit | — | $101.9M | $108.8M | $97.5M | — | — | — | — | — | — |
| R&D expense | $13.7M | $12.0M | $13.8M | — | $68.9M | $53.0M | $43.9M | $21.5M | $12.8M | $11.6M |
| Operating income | $11.5M | $16.2M | -$67.2M | $9.2M | -$87.9M | -$57.4M | -$57.3M | -$33.8M | -$21.8M | -$20.4M |
| Income tax | $4.6M | $5.3M | $8.5M | $5.1M | — | — | — | — | — | — |
| Net income | $9.9M | $17.9M | -$85.5M | $4.3M | -$87.9M | -$56.2M | -$55.2M | -$30.1M | -$21.6M | -$16.9M |
| EPS (diluted) | $0.02 | $0.05 | $-1.41 | $0.03 | $-2.87 | — | — | — | — | — |
| Operating cash flow | $1.0M | -$3.6M | $25.9M | $10.7M | -$83.8M | -$55.0M | -$43.6M | -$28.6M | -$19.9M | -$18.5M |
| Free cash flow | -$180,000 | -$6.0M | $17.4M | $5.7M | -$84.6M | — | -$43.7M | -$28.9M | -$20.0M | -$18.9M |
| Cash & equivalents | $49.2M | $11.8M | $33.5M | $25.2M | $44.3M | $30.4M | $15.4M | $31.2M | $14.5M | $10.3M |
| Inventory | $10.2M | $6.3M | $4.3M | $6.1M | — | — | — | — | — | — |
| Total assets | $219.8M | $125.4M | $116.5M | $84.8M | $55.7M | $94.8M | $98.6M | $124.9M | $39.5M | $38.1M |
| Total liabilities | $31.4M | $27.0M | $38.1M | $12.5M | $14.6M | $18.8M | $30.2M | $5.0M | $8.7M | $22.0M |
| Shareholders' equity | $62.5M | $63.3M | -$15.8M | $72.2M | $59.5M | $76.1M | $68.3M | $119.9M | $30.8M | $16.1M |
Growth · year-over-year · Revenue CAGR 96.8%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | +10.2% | -6.8% | +10.9% | +1294.0% | -65.0% | — | — | -99.4% | — | — |
| Net income growth | -44.8% | — | -2081.5% | — | — | — | — | — | — | — |
| EPS growth | -60.0% | — | -4800.0% | — | — | — | — | — | — | — |
| Free cash flow growth | — | -134.3% | +205.3% | — | — | — | — | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.